tradingkey.logo
tradingkey.logo
Search

Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the US for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

ReutersSep 26, 2025 11:02 AM
facebooktwitterlinkedin
View all comments0

- Regeneron Pharmaceuticals Inc REGN.O:

  • EVKEEZA® (EVINACUMAB-DGNB) ANGPTL3 ANTIBODY APPROVED IN THE U.S. FOR CHILDREN AS YOUNG AS 1 YEAR OLD WITH ULTRA-RARE FORM OF HIGH CHOLESTEROL

  • REGENERON PHARMACEUTICALS INC: FDA APPROVAL EXTENDS INDICATION OF EVKEEZA TO TREAT YOUNGER PATIENTS WITH HOMOZYGOUS HYPERCHOLESTEROLEMIA (HOFH)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI